Literature DB >> 26384851

Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.

Hannes Cash1, Karsten Günzel1, Andreas Maxeiner1, Carsten Stephan1, Thomas Fischer2, Tahir Durmus2, Kurt Miller1, Patrick Asbach2, Matthias Haas2, Carsten Kempkensteffen1.   

Abstract

OBJECTIVE: To examine the value of additional transrectal ultrasonography (TRUS)-guided random biopsy (RB) in patients with negative magnetic resonance imaging (MRI)/ultrasonography (US) fusion-guided targeted biopsy (TB) and to identify possible reasons for TB failure. PATIENTS AND METHODS: We conducted a subgroup analysis of 61 men with prostate cancer (PCa) detected by 10-core RB but with a negative TB, from a cohort of 408 men with suspicious multiparametric magnetic resonance imaging (mpMRI) between January 2012 and January 2015. A consensus re-reading of mpMRI results (using Prostate Imaging Reporting and Data System [PI-RADS] versions 1 and 2) for each suspicious lesion was performed, with the image reader blinded to the biopsy results, followed by an unblinded anatomical correlation of the lesion on mpMRI to the biopsy result. The potential reasons for TB failure were estimated for each lesion. We defined clinically significant PCa according to the Epstein criteria and stratified patients into risk groups according to the European Association of Urology guidelines.
RESULTS: Our analysis showed that RB detected significant PCa in 64% of patients (39/61) and intermediate-/high-risk PCa in 57% of patients (35/61). The initial mpMRI reading identified 90 suspicious lesions in the cohort. Blinded consensus re-reading of the mpMRI led to PI-RADS score downgrading of 45 lesions (50%) and upgrading of 13 lesions (14%); thus, negative TB could be explained by falsely high initial PI-RADS scores for 32 lesions (34%) and sampling of the target lesion by RB in the corresponding anatomical site for 36 out of 90 lesions (40%) in 35 of 61 patients (57%). Sampling of the target lesion by RB was most likely for lesions with PI-RADS scores of 4/5 and Gleason scores (GS) of ≥7. A total of 70 PCa lesions (67% with GS 6) in 44 patients (72%) were sampled from prostatic sites with no abnormalities on mpMRI.
CONCLUSION: In cases of TB failure, RB still detected a high rate of significant PCa. The main reason for a negative TB was a TB error, compensated for by positive sampling of the target lesion by the additional RB, and the second reason for TB failure was a falsely high initial PI-RADS score. The challenges that arise for both MRI diagnostics and prostate lesion sampling are evident in our data and support the integration of RB into the TB workflow.
© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PI-RADS version 2; multiparametric MRI; prostate cancer/diagnosis; real-time MRI/US fusion biopsy; targeted biopsy failure

Mesh:

Year:  2015        PMID: 26384851     DOI: 10.1111/bju.13327

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  28 in total

Review 1.  [Prostate biopsy: Procedure in the clinical routine].

Authors:  T Enzmann; T Tokas; K Korte; M Ritter; P Hammerer; L Franzaring; H Heynemann; H-W Gottfried; H Bertermann; M Meyer-Schwickerath; B Wirth; A Pelzer; T Loch
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

Review 2.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

3.  From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy.

Authors:  R Mager; M P Brandt; H Borgmann; K M Gust; A Haferkamp; M Kurosch
Journal:  Int Urol Nephrol       Date:  2017-06-23       Impact factor: 2.370

Review 4.  [MRI/TRUS fusion-guided prostate biopsy : Value in the context of focal therapy].

Authors:  T Franz; J von Hardenberg; A Blana; H Cash; D Baumunk; G Salomon; B Hadaschik; T Henkel; J Herrmann; F Kahmann; K-U Köhrmann; J Köllermann; S Kruck; U-B Liehr; S Machtens; I Peters; J P Radtke; A Roosen; H-P Schlemmer; L Sentker; J J Wendler; U Witzsch; J-U Stolzenburg; M Schostak; R Ganzer
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

Review 5.  [Prostate gland - what would urologists like to know from radiologists?]

Authors:  U B Liehr; D Baumunk; S Blaschke; F Fischbach; B Friebe; F König; A Lemke; P Mittelstädt; M Pech; M Porsch; J Ricke; D Schindele; S Siedentopf; J J Wendler; M Schostak
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

6.  Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.

Authors:  Akhil Muthigi; Arvin K George; Abhinav Sidana; Michael Kongnyuy; Richard Simon; Vanessa Moreno; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-08-28       Impact factor: 7.450

7.  Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.

Authors:  Michael Nguyentat; Alexander Ushinsky; Alessandra Miranda-Aguirre; Edward Uchio; Chandana Lall; Layla Shirkhoda; Thomas Lee; Christopher Green; Roozbeh Houshyar
Journal:  Curr Probl Diagn Radiol       Date:  2017-10-12

8.  Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Authors:  Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots
Journal:  Cochrane Database Syst Rev       Date:  2019-04-25

Review 9.  Internal Fusion: exact correlation of transrectal ultrasound images of the prostate by detailed landmarks over time for targeted biopsies or follow-up.

Authors:  Yanqi Xie; Theodoros Tokas; Björn Grabski; Tillmann Loch
Journal:  World J Urol       Date:  2017-12-27       Impact factor: 4.226

Review 10.  Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology.

Authors:  Lacey R McNally; Megan Mezera; Desiree E Morgan; Peter J Frederick; Eddy S Yang; Isam-Eldin Eltoum; William E Grizzle
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.